Proposed framework addresses diagnostic and therapeutic gaps for young adults with MASLD, indicating urgent public health implications.
Metabolic dysfunction-associated steatotic liver disease (MASLD) increasingly affects young adults, yet this population remains excluded from therapeutic trials and inadequately served by age-biased diagnostic medicine framework for “Generation MASLD” addressing three critical gaps: diagnostic tool failure in younger patients, therapeutic evidence derived exclusively from middle-aged cohorts, and absent transition-of-care frameworks. Urgent action is needed to prevent an emerging public health crisis.
No takes yet. Share an insight, caveat, or question.
Victoria Sze Min Ekstrom (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: